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Further, Kaplan-Meier survival analysis failed to demonstrate significant differences in survival at the cut off chosen. In conlusion PAPPA was not useful as a predictor of outcome in patients with chronic renal impairment attending a pre-dialysis clinic 4 (6%) 
(5%)
4
METHODS:
Serum samples and skin biopsies were examined from 54 patients with SSc and 12 healthy controls. 20 had early (within 3 years from onset) diffuse cutaneous SSc (dcSSc), 14 late dcSSc and 20 limited cutaneous SSc (1cSSc). Levels of MCP-1 in serum were measured by commercial ELISA. Expression of MCP-1 and its major receptor CCRZ in snap-frozen skin biopsies was determined by immunohistochemistry. Fibroblasts were cultured from a randomly selected subgroup of early dcSSc and culture supernatants examined by western blot. Chemokine receptor expression (CCR2, CXCRZ and CCRS) on fibroblasts was determined by flow cytometry, comparing receptor-specific antibody binding with an isotype matched control.
RESULTS:
MCP-1 serum levels (meansem) were significantly elevated in SSc patients (342&4 pg/ml) compared to controls (132i26pg/ml, p=0.002) and were highest in the early dcSSc subset (433i47 pg/ml) compared to late dcSSc (307+_41 pg/ml) and lcSSc (276228 pg/ml). Western Blot analysis of cultured fibroblasts supernatants confirmed substantial overproduction (meanksem) of MCP-I by cells from early dcSSc (n=8) (RDU=37.5+11.2) compared with normal fibroblasts (RDU=8.3d2.0) (~3 . 0 0 2 ) . lmmunohistochemistry showed strong expression of MCP-1 and CCRZ in skin from all patients with early stage dcSSc. but expression in late stage dcSSc and lcSSc was weaker or absent. By flow cytometry CCRZ was detectable only on early-stage dcSSc, both normal and SSc fibroblasts expressed CXCR2 whereas CCR5 was not detected.
CONCLUSION:
High serum levels of MCP-I in early diffuse disease, overproduction by fibroblasts cultured from early-stage dcSSc biopsies and CCR2 expression on fibroblasts confirm upregulation of the MCP-I ligand-receptor axis in SSc and suggest that chemokine antagonism may be a logical therapeutic strategy.
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The role of graft expressed Fas-Ligand on allograft rejection
MD Dooldeniya, F Morgan, PJ Dyson, AN Warrens, Imperial College
Apoptosis acts as both a control and effector mechanism with in the immune system. The best-described receptor-ligand combination that induces this, comprises one member of the TNF receptor family, Fas, and one member of the TNF ligand family, Fas-ligand (FasL) . This receptor/ligand combination contributes to immune privilege and acts as a homeostatic mechanism within the immune system. Pathological expression of FasL on certain tumour lines leads to immune evasion.
In the light of this evidence of modulation of the immune response by the expression of FasL we hypothesised that graft parenchyma uses the expression of FasL as a protective mechanism in inflammation.
In a mouse model of skin transplantation, we have shown that FasL is upregulated during rejection, and that the presence of FasL leads to a prolongation of graft survival across a single (p=0.002) or multiple minor histocompatibility mismatches.
Considering the possible level at which FasL has its effect, there were many more infiltrating cells in the FasL than the wild type allograft. Using animals that had been primed with wild type skin, there was much more rapid rejection of FasL than wild type allografts. Suggesting that wild type grafts were afforded some degree of protection from the efferent limb of the immune response by the presence of FasL. This implies that FasL acts locally to reduce the immune response.
We looked at the afferent limb of the immune response in a cellular model. Wild type and FasL male target cells were mixed with female control cells at a ratio of 1:l and introduced intravenously into a female wild type recipient. The recipient mice then went on to receive a second inoculation of a 1:I mixture of male and female wild type cell suspension. There was an increased rate of loss of the male cells when the recipients had been primed initially with FasL cells, as well as an increase in the number of male antigen specific CD8' cells identified with MHC peptide tetramer staining. This implies that the nature of the immune response induced varies to some degree on the basis of the FasL expression by the priming cell.
An understanding of the physiological role of FasL in inflammation will help us harness it as a modulatory agent in transplant biology.
